	US 12,263,245 B2
	Immunomodulating treatments of body cavities
Caretha L. Creasy, Philadelphia, PA (US)
Assigned to UROGEN PHARMA LTD., Ra'anana (IL)
Filed by UROGEN PHARMA LTD., Ra'anana (IL)
Filed on May 16, 2024, as Appl. No. 18/665,612.
Claims priority of provisional application 63/502,418, filed on May 16, 2023.
Prior Publication US 2024/0382420 A1, Nov. 21, 2024
Int. Cl. A61K 9/06 (2006.01); A61K 31/403 (2006.01); A61K 31/4738 (2006.01); A61K 31/7072 (2006.01); A61K 47/10 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC A61K 9/06 (2013.01) [A61K 31/403 (2013.01); A61K 31/4738 (2013.01); A61K 31/7072 (2013.01); A61K 47/10 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01)]

21 Claims

1. A method for treating a urinary tract cancer, comprising:

locally administering to a subject in need thereof a pharmaceutical composition formulated to provide sustained release of zalifrelimab over a period of about 2 to about 24 hours, wherein the pharmaceutical composition comprises an admixture of:

i. a thermoreversible hydrogel comprising 20%-32% (w/w) of poloxamer and water; and

ii. a solution comprising about 100 mg to about 700 mg zalifrelimab, thereby producing a detectable zalifrelimab urine void concentration of at least 20 μg/mL after at least 2 hours of administration,

thereby treating the urinary tract cancer.